Group Information: A list of the Diabetic Retinopathy Clinical Research Network (DRCR.net) investigators and staff participating in this protocol was published in Ophthalmology. 2008;115(9):1447-1449, 1449.e1-1449.e10, and a current list appears at http://www.drcr.net.
Financial Disclosure: A complete list of all DRCR.net investigator financial disclosures can be found at http://www.drcr.net.
Funding/Support: This work was supported through a cooperative agreement from the National Eye Institute and the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, US Department of Health and Human Services (grants EY14231, EY018817, and EY14229). Allergan, Inc provided the triamcinolone and topical antibiotics after successfully competing for a request for proposals issued by DRCR.net for a company to provide a preservative-free triamcinolone for the study. Allergan, Inc has provided unrestricted funds to DRCR.net for its discretionary use.
Role of the Sponsor: The funding organization participated in oversight of the conduct of the study and review of the manuscript but not directly in the design of the study, the conduct of the study, data collection, data management, data analysis, interpretation of the data, or preparation of the manuscript. As per the DRCR.net Industry Collaboration Guidelines (http://www.drcr.net), DRCR.net had complete control over the design of the protocol, ownership of the data, and all editorial content of presentations and publications related to the protocol.